MedicalResearch.com Interview with:
Ira Kalfus, M.D.,
Medical Director
RedHill BioPharma
Immunohistochemical staining of H. pylori from a gastric biopsy - Wikipedia image
MedicalResearch.com: What is the background for this announcement? Would you briefly explain the significance of H. pylori infections? What are the potential complications of infection with this bacteria?
Response: Heliobacter pylori is one of the most prevalent human pathogens. H. pylori bacterial infection affects over 50% of the adult population worldwide1 and 30-40% of the U.S. population2, with an estimated 2.5 million patients treated annually in the U.S.3 People infected with H. pylori may suffer from gastritis and have an increased risk of developing ulcers and gastric cancers. In fact, H. pylori is classified as a group I carcinogen by the International Agency for Research on Cancer in part because it is the strongest risk factor for the development of gastric cancer.4
Eradication of H. pylori is becoming more difficult. Current standard-of-care therapies fail in approximately 30-40% of patients, who remain H. pylori positive. This is due to increasing resistance of H. pylori to antibiotics commonly used in standard combination therapies5. Clarithromycin-resistant H. pylori was formally categorized by the World Health Organization as a pathogen for which there is a high priority need to develop new treatments.6
The pervasive nature of H. pylori, the great health risks that it poses and the rapid development of resistance to currently available therapies speak to the great unmet medical need for new treatments that are effective at eradicating H. pylori infections. We set out to develop TALICIA®(RHB-105) as an answer to this growing public health concern with the hopes that it could someday be adopted as a new first-line therapy for all people affected by H. pylori infection.
(more…)MedicalResearch.comInterview with:
Professor John McGrath
Niels Bohr Professor
National Centre for Register-based Research
Aarhus University
Queensland Brain Institute
University of Queensland
Brisbane AustraliaQueensland Centre for Mental Health Research
The Park Centre for Mental Health Australia
MedicalResearch.com: What is the background for this study?
What are the main findings?
Response: We know that people born in winter and spring have an increased risk of later developing schizophrenia. But, we were not sure why. We know that vitaminD, the sunshine hormone, is more likely to be low in winter and spring, so wedeveloped a way to test for vitamin D in stored neonatal blood sample.
(more…)Accreditation standards may be an effective policy lever to increase diversity in the physician workforce. ...
Titanium’s vast array of uses in medical science, as well as other fields, points toward our civilization heading into a...